Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

  • Author: Philip N. Newsome, PhD, FRCPE (More Info)
  • Editor In Chief: Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
  • Last Reviewed: 8/23/19 (What's New)

Summary

  • Multiple agents are in late-phase clinical investigation for management of patients with NAFLD and NASH
    • Investigational FXR agonists include obeticholic acid, tropifexor (LJN452), and cilofexor (GS-9674)
    • Other investigational agents include the PPAR-α/δ agonist elafibranor and the liver ACC inhibitor firsocostat (GS-0976)

Action required